## 7-5/2013/EU/WC-0138 Government of India Directorate General of Health Services Central Drugs Standard Control Organisation (International Cell)

FDA Bhawan, Kotla Road, New Delhi-110002 Dated

0 | APR 2021

To

M/s. Cipla Limited Plot No. 285, 286 and 287 Bommasandra – Jigani Link Road Industrial Area, KIADB, 4th Phase, Bengaluru – 560 105

SUB:- Written Confirmation of M/s. Cipla Limited, Plot No. 285, 286 and 287, Bommasandra – Jigani Link Road, Industrial Area, KIADB, 4<sup>th</sup> Phase, Bengaluru – 560 105 as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

0/L

Please refer to your application submitted to CDSCO, Bangalore Sub-Zone office, and the recommendation received from DDC (I), Bangalore Sub-Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

- The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
- The manufacturer is subject to regular, strict and transparent controls and to the
  effective enforcement of Good Manufacturing Practice, including repeated and
  unannounced inspections, so as to ensure a protection of public health equivalent
  to that in the EU.
- 3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
- 4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
- 5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.

- 6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
- 7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
- 8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.


Annexure No.	No. of Products	Date of Issue	Valid Upto
ut eliment	22	09.08.2019	SERVER BEREIT
2	01		08.08.2022
		N 1 APR 2021	08.08.2022

Yours faithfully,

Vh

(Dr. V. G. Somani) Drugs Controller General (India)

85-20-20 21



MINISTRY OF HEALTH & FAMILY WELFARE Central Drugs Standard Control Organization

**CERTIFICATE NO.:** 

WC-0138

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site:

M/s. Cipla Limited,

Plot No. 285, 286 and 287

Bommasandra - Jigani Link Road Industrial Area, KIADB, 4th Phase

Bengaluru - 560 105

List of APIs

Sr. No.	Active substance (s)	Activity(ies)
1.	Imatinib Mesylate Ph. Eur.	Manufacturing & Packing

ITEM(S) One (01) ONLY

The Written Confirmation remains valid until: 08.08.2022

Signature

and date Stamp

0 1 APK 2021